Secondary tabs
Contact details
Mikael Ohlin
Main
Publications
Data source publications
Studies
List of studies that have been conducted using the data source
- Strattera patient exposures and adherence in the United Kingdom, Germany, the Netherlands, and Sweden: 2016 Bi-annual assessment report. (B4Z-MC-B025)
- A population-based cohort study using an existing database to evaluate the association between latanoprost use and primary malignant ocular melanoma and facial cutaneous melanoma
- Use of Nalmefene (Selincro®) in European databases: Cohort design using longitudinal electronic medical records or claims databases
- Incidence and outcome of paracetamol poisoning
- An Observational Post-Authorization Safety Study (PASS) of MOVENTIG® (Naloxegol) Drug Utilization in Selected European Populations
- Pan European Multi-Database Bladder Cancer Risk Characterisation Study
- Strattera patient exposures and adherence in the United Kingdom, Germany, the Netherlands, and Sweden: 2014 Bi-annual assessment report
- A pharmacoepidemiological study to examine patient characteristics, drug utilization pattern and crude incidence rates of selected outcomes in new users of ticagrelor,clopidogrel and prasugrel in national Swedish registries.
- RRA-17425, Risperidone Exposure and the Risk of Osteoporosis-related Fractures – Sweden
- A multinational active safety surveillance study of crizotinib in Europe and the United States
- Cilostazol Drug Utilisation Study
- An observational cohort study to evaluate the risk of adverse pregnancy outcomes in patients treated with etanercept compared to those not treated with etanercept or other biologics using merged data from Sweden, Denmark and Finland
- Treatment and outcomes among patients with atrial fibrillation and acute coronary syndrome in Sweden
- Safety Data on Etoricoxib From Swedish Registries of Spondyloarthropathy/Ankylosing Spondylitis Patients (MK-0663-159; EP07013.013.11.082)
- Strattera patient exposures and adherence in the United Kingdom, Germany, the Netherlands, and Sweden: 2018 Bi-annual assessment report (B4Z-MC-B026)
- A Drug Utilization Study of Xofigo Use in Sweden
- Post-authorization Safety Program Using the Swedish National Registers—A Validation Study of Cardiovascular and Neoplasm Events in Users of PharmacologicalTreatments for Overactive Bladder
- A Nationwide Post-Marketing Study on the Safety of Abatacept Treatment in Sweden Using the SRQ Register
- Comparative Assessment of VTE and Other Risks among Patients with Rheumatoid Arthritis treated with Baricitinib versus Tumor Necrosis Factor Inhibitors: A Multi-database Observational Cohort Study
- Post-authorization Safety Study Evaluation of Neoplasm Events in Users of Mirabegron and Other Treatments for Overactive Bladder : Core Common Protocol
- A Joint Drug Utilisation Study (DUS) of valproate and related substances, in Europe, using databases
- Beyond Pooled – Part of the BEYOND study program (Benefit of NOACs study of non-valvular AF patients in nordic countries) (BEYOND Pooled (Denmark, Norway, Sweden))
- Pharmacoepidemiological study (Drug Utilization Study) of JAYDESS use in routine clinical practice in Sweden (Jaydess DUS)
- Linaclotide Utilisation Study in Selected European Populations
- Post-authorization Safety Study Evaluation of Cardiovascular Events in Users of Mirabegron and Other Treatments for Overactive Bladder
- Drug Utilisation Study of conjugated oestrogens/bazedoxifene (CE/BZA) in the European Union (EU)
- A Population-based Cohort Study of Pregabalin to Characterize Pregnancy Outcomes
- Extrapyramidal symptoms in patients treated with Abilify Maintena®: Cohort study with a 2-year follow-up using European automated healthcare databases
- Post-authorization Safety Surveillance Program for Sarilumab using existing European Rheumatoid Arthritis Registries in Germany, Spain, Sweden and United Kingdom
- Utilisation of dulaglutide in European countries: A cross-sectional, multi-country and multi-source drug utilisation study using electronic health record databases (H9X-MC-B010)
- The use of NOAC for atrial fibrillation in patients after biologic valvular replacement or valvuloplasty
- Post-Authorisation Safety Study of Agomelatine and the Risk of Hospitalisation for Acute Liver Injury
- Linaclotide Safety Study for the Assessment of Diarrhoea—Complications and Associated Risk Factors in Selected European Populations with IBS-C
- Retrospective registry study evaluating the safety of melatonin use in children and adolescents with attention deficit hyperactivity disorder (ADHD) in Sweden (Safety of melatonin in children with ADHD)
- Pancreatic Cancer and Thyroid Cancer Risks with Dulaglutide Treatment
- A Retrospective Cohort Study to Assess the Safety of Baricitinib Compared with Other Therapies Used in the Treatment of Rheumatoid Arthritis in Nordic Countries (I4V-MC-B011)
- Cohort Study of the Relative Incidence of Major Cardiovascular Events Among Patients Initiating Prucalopride Versus a Matched Comparator Cohort
- A pharmacoepidemiological study of rivaroxaban use and potential adverse outcomes in routine clinical practice in Sweden
- Cohort Study of the Incidence of Major Cardiovascular Events in New Adult Users of Lisdexamfetamine and Remote Adult Users of Other ADHD Treatments
- The BRodalumab Assessment of Hazards: A Multinational Safety (BRAHMS) study in electronic healthcare databases
- Association between androgen deprivation therapy and excess mortality after covid-19 in patients with prostate cancer
- Drug utilization study for Elvanse® / Tyvense® / Elvanse® Adult in Europe
- Real-world evidence for non-valvular atrial fibrillation patients treated with oral anticoagulation in the Nordics (REATTAIN)
- Observational Studies in Cancer Associated Thrombosis for Rivaroxaban in SwEden (OSCAR-SE)
- A Comparative Observational Study Evaluating the Incidence Rate of Endometrial Cancer in Women aged 50 Years and Over Who Use Low dose Vaginal Estrogen Unopposed by a Progestogen: A Post-authorization Safety Study in the United States and Sweden (Low dose vaginal estrogen and endometrial cancer)
- Venous Thromboembolism Treatment (VOLT)
- EPID Multiple Sclerosis Pregnancy study - Pregnancy outcomes in Multiple Sclerosis populations exposed and unexposed to interferon beta - a register-based study in the Nordic countries
- A Post-Authorisation Safety Study of the Utilisation and Prescribing Patterns of Xeljanz® (tofacitinib) in the European Union Using Secondary Data Sources
- A post-authorisation safety study (PASS) to evaluate the long-term cardiovascular and psychiatric safety profile of methylphenidate (MPH) in adult patients with attention deficit/hyperactivity disorder (ADHD) in European Countries (PASS on methylphenidate in adults)
- Long term, prospective, observational cohort study evaluating the safety profile in patients with highly active relapsing multiple sclerosis (RMS) newly started on oral cladribine − CLARION
- Post-authorisation safety study of NOCDURNA for the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria: A multi-country cohort study using secondary data. (NOCDURNA PASS)
- A post-marketing registry-based prospective cohort study of long-term safety of risankizumab in Denmark and Sweden
- Drug Utilisation Study of Intuniv® (guanfacine extended release) in European Countries, Study protocol I: Database study (Intuniv data base study Europe)
- Post-authorisation safety study to assess the risk of urinary tract malignancies in relation to empagliflozin exposure in patients with type 2 diabetes: a multi-database European study (PASS DiabCancer)
- Dulaglutide and Potential Risks of Pancreatic Cancer and Thyroid Cancer: A Non-Interventional PASS (H9X-MC-B013)
- A non-interventional register-based comparative effectiveness study of rhFSH-alfa reference product vs. highly purified human menopausal gonadotropin or rhFSH-alfa biosimilar products for ovarian stimulation in in vitro fertilization or intracytoplasmic sperm injection treatment in Denmark and Sweden – The Nordic Follitropin Alfa Comparative Effectiveness Study (NORD-FACE)
- Prospective observational study to assess the long term safety profile of venetoclax in a Swedish cohort of Chronic Lymphocytic Leukaemia (CLL) patients
- Establish an EU catalogue of sources of real-world data, characterised by a common set of metadata and data quality measurements
- A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients who Initiated Exenatide as Compared with those who Initiated Other non-Glucagon-Like Peptide 1 Receptor Agonists based Glucose Lowering Drugs (EXCEED)
- An Active Surveillance, Post Authorization Safety Study (PASS) of Serious Infection, Malignancy, Cardiovascular (CV) and Other Safety Events of Interest among Patients Treated with Tofacitinib for Moderately to Severely Active Rheumatoid Arthritis (RA) within the Swedish, Population based, Anti Rheumatic Treatment in Sweden (ARTIS) register. (Safety of tofacitinib in ARTIS)
- A Population-based Study of the Safety of Gabapentin Use During Pregnancy
- Persistence and adherence to novel systemic pharmacological treatment of moderate to severe psoriasis vulgaris and psoriatic arthritis – A register-based cohort study in Finland and Sweden
- Adherence to the major classes of anthypertensive theraphy (AMCA)
- Population-based retrospective nested case-control study evaluating effectiveness of GARDASIL™ against adult-onset recurrent respiratory papillomatosis in Sweden (V503-088)
- A Non-interventional Observational Longitudinal Post-Authorization Safety Study (PASS) of SIMPONI® in Treatment of Ulcerative Colitis using Nordic National Health Registries (MK-8259-013)
- Long-Term Post-Marketing Observational Study of the Safety of Roflumilast
- Evaluation of the effectiveness of pregnancy prevention programme (PPP) for oral retinoids (acitretin, alitretinoin, and isotretinoin): a European before-after drug utilization study (DUS) using secondary data
- Multi-country non-interventional study on the effectiveness and safety of Empagliflozin in adult patients with type 2 diabetes in Europe and Asia
- An Observational Longitudinal Post-authorization Safety Study of STELARA® in the Treatment of Psoriasis and Psoriatic Arthritis: Analysis of Major Adverse Cardiovascular Events (MACE) using Swedish National Health Registers (QUANTIFY STELARA MACE)
- DRUG UTILISATION AND SAFETY STUDY OF MYSIMBA/CONTRAVE IN EUROPE AND THE UNITED STATES (NB-451 DUS)
- Xarelto Paediatric VTE PASS Drug Utilization Study: An observational, longitudinal, multi-source drug utilization safety study to evaluate the drug use patterns and safety of rivaroxaban oral suspension in children under two years with venous thromboembolism (XAPAEDUS)
- Kesimpta (ofatumumab) pregnancy and infant safety study using real world data
- Cohort Study of Long-term Safety of Upadacitinib in the Treatment of Atopic Dermatitis in Denmark and Sweden
- Cohort Study of Long-term Safety of Upadacitinib for the Treatment of Ulcerative Colitis and Crohn’s Disease in a Real-world Setting in Europe
- Post-AuthorisationActive Safety Surveillance Program Among Patients Treated With Tofacitinib for Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Juvenile Psoriatic Arthritis (PsA) Using Nationwide Swedish Healthcare Registers
- An Active Surveillance Study to Monitor the Real-World Long-term Safety of Somatrogon Among Paediatric Patients in Europe
- Drug Utilization Study Evaluating Additional Risk Minimisation Measures for Upadacitinib in the Treatment of Ulcerative Colitis in Europe
- Comparative Cohort Study of Long-term Safety Outcomes of Risankizumab Compared to Biologic Treatments for Crohn’s Disease in a Real-world Setting in Sweden and Denmark
- Drug Utilization Study Evaluating Additional Risk Minimization Measures for Upadacitinib in the Treatment of Atopic Dermatitis in Europe